ICIOL Chemicals & Pharmaceuticals524164Quarterly results

Q2 FY27 results: highest-ever quarterly revenue, EBITDA and PAT; revenue up 40.1%

Q2 FY27 revenue ₹795.0 Cr, up 40.1% YoY; EBITDA ₹114.9 Cr (up 79.6%); PAT ₹65.0 Cr (up 116.8%).

By ScoutQuest · Fri 30 Oct 2026, 8:10 PM IST · 2 min read

Q2 FY27 Revenue

₹795.0 Cr, up 40.1% YoY

Q2 FY27 EBITDA

₹114.9 Cr, up 79.6%

Q2 FY27 PAT

₹65.0 Cr, up 116.8%

What the company reported

IOL Chemicals and Pharmaceuticals Ltd released a press note on its unaudited standalone financial results for the quarter and half year ended 30th September 2026. The release states that the quarter delivered the company's highest-ever quarterly revenue, EBITDA and PAT.

Q2 FY27 numbers (standalone, year-on-year)

• Revenue from operations: ₹795.0 Cr vs ₹567.5 Cr, up 40.1%
• EBITDA: ₹114.9 Cr vs ₹64.0 Cr, up 79.6%
• EBITDA margin: 14.4% vs 11.1%, up 321 bps
• PAT: ₹65.0 Cr vs ₹30.0 Cr, up 116.8%
• PAT margin: 8.1% vs 5.2%, up 290 bps

Half year at a glance

For H1 FY27, revenue from operations was ₹1551.3 Cr against ₹1119.2 Cr, up 38.6%. EBITDA was ₹226.6 Cr against ₹133.5 Cr, up 69.7%, and PAT was ₹129.5 Cr against ₹64.0 Cr, up 102.5%. Margins for the half year stood at 14.5% (EBITDA) and 8.3% (PAT), against 11.8% and 5.6% respectively.

How the two businesses did

The company reports two segments.

• Pharmaceuticals: Q2 FY27 revenue ₹472.8 Cr with EBIT of ₹68.1 Cr; the corresponding year-ago quarter had revenue of ₹336.4 Cr and EBIT of ₹35.5 Cr. For H1 FY27, revenue was ₹942.2 Cr with EBIT of ₹136.9 Cr, against ₹665.7 Cr and ₹75.5 Cr a year earlier.
• Chemicals (net of intersegment): Q2 FY27 revenue ₹322.3 Cr with EBIT of ₹23.2 Cr, against revenue of ₹231.2 Cr and EBIT of ₹5.1 Cr in Q2 FY26. H1 FY27 revenue was ₹609.1 Cr with EBIT of ₹40.5 Cr, against ₹453.5 Cr and ₹11.0 Cr.

What management said

Joint Managing Director Mr. Vikas Gupta attributed the quarter to healthy demand across key products and improved operational efficiencies, with better product mix and operating efficiencies contributing to a 321-basis-point year-on-year expansion in EBITDA margin. He also noted that the non-Ibuprofen portfolio grew approximately 70% year-on-year and accounted for 45% of pharmaceutical revenue in the quarter, compared with 38% in Q2 FY26. For Chemicals, he said segment EBIT contribution rose to approximately 7% from 1% in the same quarter last year. On the way ahead, he referred to forward integration into CDMO and formulation manufacturing and said priorities remain portfolio diversification, operational excellence and higher-value manufacturing.

About the company

IOLCP, established in 1986 and headquartered in Ludhiana, Punjab, makes Active Pharmaceutical Ingredients and specialty chemicals. The release describes it as the world's largest producer of Ibuprofen with a 30% global market share, among the largest global producers of Iso Butyl Benzene, and a key manufacturer of Ethyl Acetate in India, with exports to over 80 countries.

What a retail investor can take away

The release shows a quarter of broad-based growth: both segments reported higher revenue and operating profit than a year earlier, and profit growth ran ahead of revenue growth. The stated drivers were demand, product mix and operating efficiencies, along with a rising share of non-Ibuprofen products in the pharmaceutical business. The release also carries a safe harbour statement noting that forward-looking statements are subject to risks and actual results may differ.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev